Michael Gilman, Ph.D. is President and CEO of Stromedix, Inc. and most recently served as Executive Vice President of Research at Biogen Idec, Inc. During his six-year tenure at Biogen Idec, from 1999 to 2005, Dr. Gilman managed discovery research including inflammatory and autoimmune diseases, and cancer. From 1994 to 1999, Dr. Gilman served as Executive Vice President and Chief Scientific Officer of Ariad Pharmaceuticals Inc. where he was responsible for drug discovery activities to develop novel gene- and cell-regulation technologies.
Earlier in his career, Dr. Gilman was a principal investigator at Cold Spring Harbor Laboratory where he ran an active research programs in growth control and cancer, signal transduction and gene transcription and held adjunct academic appointments at SUNY Stony Brook. He earned a Ph.D. in Biochemistry from the University of California, Berkeley, and holds an S.B. in Life Sciences from the Massachusetts Institute of Technology.
|